Today there are just a handful of treatments for patients with myelodysplastic syndrome (MDS), a condition that involves ineffective blood cell production. Patients often develop severe anemias and require frequent blood transfusions. In the worst case scenario, MDS can evolve into especially lethal cases of acute myeloid leukemia (AML).
A white knight may be on the horizon in the form of a drug called Estybon. A couple of years back, LLS recognized the potential in Estybon and partnered with Onconova Therapeutics to accelerate the drug’s development and get it to patients faster.
Today, LLS dollars help support a large, international clinical trial that, if successful, could lead to the drug’s approval by the FDA and its broad availability to MDS patients.
It gets better. Estybon may have even broader application. Clinical trials are underway for patients with lymphomas and chronic lymphoid leukemia (CLL). Researchers have also seen promising early results for patients with other types of cancer, including pancreatic cancer.
A solid investment with tremendous near-term results made possible by supporters like you!